47,648 Shares in Immunovant, Inc. (NASDAQ:IMVT) Acquired by Aquatic Capital Management LLC

Aquatic Capital Management LLC purchased a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 47,648 shares of the company's stock, valued at approximately $1,180,000.

Other hedge funds also recently bought and sold shares of the company. FMR LLC increased its holdings in shares of Immunovant by 4.5% in the 4th quarter. FMR LLC now owns 13,097,915 shares of the company's stock worth $324,435,000 after buying an additional 560,344 shares during the last quarter. Vanguard Group Inc. increased its stake in Immunovant by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 6,679,414 shares of the company's stock worth $165,449,000 after acquiring an additional 20,614 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Immunovant by 53.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,117,234 shares of the company's stock valued at $126,754,000 after purchasing an additional 1,786,217 shares during the period. Alpine Global Management LLC raised its position in Immunovant by 14.7% during the fourth quarter. Alpine Global Management LLC now owns 2,158,904 shares of the company's stock valued at $53,476,000 after purchasing an additional 276,200 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Immunovant by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 1,515,020 shares of the company's stock valued at $37,536,000 after purchasing an additional 4,094 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company's stock.

Insider Buying and Selling at Immunovant

In other Immunovant news, CFO Eva Renee Barnett sold 2,993 shares of the company's stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $14.89, for a total transaction of $44,565.77. Following the completion of the sale, the chief financial officer now owns 396,774 shares in the company, valued at $5,907,964.86. This represents a 0.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Andrew J. Fromkin sold 8,000 shares of Immunovant stock in a transaction on Friday, March 7th. The shares were sold at an average price of $19.60, for a total value of $156,800.00. Following the completion of the transaction, the director now owns 91,913 shares in the company, valued at $1,801,494.80. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,682 shares of company stock valued at $753,419. Company insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Guggenheim restated a "buy" rating on shares of Immunovant in a report on Thursday, March 20th. UBS Group restated a "neutral" rating and issued a $17.00 target price (down previously from $38.00) on shares of Immunovant in a report on Tuesday, April 22nd. Cantor Fitzgerald upgraded shares of Immunovant to a "strong-buy" rating in a report on Tuesday, March 4th. Wolfe Research lowered shares of Immunovant from an "outperform" rating to a "peer perform" rating in a research report on Friday, January 3rd. Finally, Jefferies Financial Group began coverage on Immunovant in a research report on Monday, March 3rd. They set a "hold" rating and a $20.00 target price for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $38.33.

Immunovant Trading Down 0.6 %

Shares of NASDAQ IMVT traded down $0.10 during trading hours on Friday, reaching $15.80. The stock had a trading volume of 906,005 shares, compared to its average volume of 1,200,383. Immunovant, Inc. has a 52-week low of $12.72 and a 52-week high of $34.47. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -6.03 and a beta of 0.81. The business's fifty day moving average price is $17.01 and its two-hundred day moving average price is $22.64.

Immunovant (NASDAQ:IMVT - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.08). Equities research analysts anticipate that Immunovant, Inc. will post -2.69 earnings per share for the current fiscal year.

Immunovant Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.